Recent Updates
Recently added Catalysts
BOLT Negative Sentiment Score: 25/100

BOLT ALERT: Bragar Eagel & Squire, P.C. is Investigating Bolt Biotherapeutics, Inc. on Behalf of Bolt Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation into Bolt Biotherapeutics, Inc. on behalf of its stockholders due to potential violations of federal securities laws. The investigation arises from claims that the company made materially false statements regarding its business operations and the effectiveness of its product BDC-1001. This situation raises concerns about the company's future, including possible workforce reductions and leadership changes. The law firm invites affected investors to reach out to learn more about their rights and potential claims.

Market Sentiment Analysis

CONCERNS & RISKS

  • Bolt is under investigation for potential violations of federal securities laws.
  • Allegations include materially false and misleading statements about the company's business and product effectiveness.
  • Concerns over bolt's product BDC-1001's effectiveness against previously stated success criteria.
  • The company faces risks of leadership transitions and workforce reductions.

Full Press Release Details

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT) on behalf of Bolt stockholders. Our investigation concerns whether Bolt has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt’s product pipeline, on which the Company primarily relies to sustain its business model; (iii) all of the foregoing subjected the Company to a heightened risk of disruptive leadership transitions and substantial workforce reduction; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Bolt shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

bolt biotherapeutics

Frequently Asked Questions

What investigation is Bragar Eagel & Squire conducting?

They are investigating potential claims against Bolt Biotherapeutics for possible violations of federal securities laws.

What misleading information was reported about Bolt's product BDC-1001?

It was falsely stated that BDC-1001 was effective and would meet success criteria, which was not true.

Who can contact Bragar Eagel & Squire for more information?

Any Bolt stockholder who faced losses or has information can reach out to the firm.

Where is Bragar Eagel & Squire located?

The firm has offices in New York and California.

Is there a cost for contacting Bragar Eagel & Squire?

No, there is no cost or obligation to contact them regarding the investigation.

Last updated: Jul 10, 2024